Cymbalta for Fibromyalgia: The REMS That Wasn't

FDA will not necessarily require a formal Risk Evaluation & Mitigation Strategy for drugs that already have mandatory consumer medication guides. That means Lilly has a freer hand to compete against Lyrica in an important new market--and now the question becomes what FDA might do to impose tighter controls on the Pfizer brand.

FDA’s approval of Eli Lilly & Co.’s Cymbalta (duloxetine) for treatment of fibromyalgia sets another precedent in the new era of Risk Evaluation & Mitigation Strategies: the agency will not necessarily seek a formal REMS for products already accompanied by mandatory medication guides.

Cymbalta received FDA approval for the new indication on June 13. Like all antidepressants, duloxetine carries a boxed warning in...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Agency Leadership

More from Pink Sheet